Alcon Included in New US Medicaid Drug Pricing Agreements
Alcon was included in new US drug pricing agreements announced by the Trump administration with nine major pharmaceutical companies. The deals reset how Alcon’s outpatient drugs are priced for state Medicaid programs, using international benchmarks. The change may reduce Alcon’s margins on US government business and could shape future regulator pricing discussions, with effects expected to appear in upcoming segment disclosures.